Fierce Pharma
DECEMBER 20, 2022
2023 forecast: With Novo's Wegovy on a supply rebound, 2023 offers course correction and obesity showdown with Lilly. fkansteiner. Tue, 12/20/2022 - 10:26.
MedCity News
DECEMBER 20, 2022
As with most industries, healthcare should consider adopting a zero-trust approach. This security measure can help decrease an organization’s attack surface, create accurate response automation and prevent the compromise.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 20, 2022
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. kdunleavy. Tue, 12/20/2022 - 13:39.
MedCity News
DECEMBER 20, 2022
With the projection that the U.S. may spend up to $27.9 billion annually on low-value screening, testing, and procedures considered waste, there needs to be a new approach to how the lab industry develops test menus from which physicians order labs.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
DECEMBER 20, 2022
In new lawsuit, J&J's talc subsidiary takes issue with expert witness testimony. esagonowsky. Tue, 12/20/2022 - 11:18.
MedCity News
DECEMBER 20, 2022
I write this because of my own personal experience with stealing prescription drugs while employed as a nurse, which led to me serving a four-month jail sentence and losing the career of my dreams.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
DECEMBER 20, 2022
Inflation and shrinking operational margins are among the key factors that will influence hospitals and health systems’ strategies in 2023. To deal with this, more hospitals will merge with other systems, predicted Tina Wheeler, Deloitte’s leader for its healthcare sector.
Fierce Pharma
DECEMBER 20, 2022
2023 forecast: As the COVID-19 vaccine market evolves, what's next for the top players? zbecker. Tue, 12/20/2022 - 13:48.
MedCity News
DECEMBER 20, 2022
Many providers think their telehealth program increases the workload for nurses and support staff, according to a recent report. In 2023, hospitals and physician practices will have to focus on making their telehealth workflows more efficient, which may involve partnering with third-party administrators.
Fierce Pharma
DECEMBER 20, 2022
Vaxess' flu vaccine patch passes early clinical test, clearing path for further development. ntaylor. Tue, 12/20/2022 - 04:57.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
DECEMBER 20, 2022
Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
Fierce Pharma
DECEMBER 20, 2022
With bigger fish to fry, Eisai unloads US rights to epilepsy drug Fycompa to Catalyst. kdunleavy. Tue, 12/20/2022 - 09:44.
MedCity News
DECEMBER 20, 2022
In most cases, healthcare organizations choose not to let employees go following an RPA implementation. Instead, they reallocate their (human) resources where they can be better used, boosting employee satisfaction and easing staff burnout.
Fierce Pharma
DECEMBER 20, 2022
Teetering on the edge, Midatech plots pivot beyond drug delivery platform with Bioasis buyout. ntaylor. Tue, 12/20/2022 - 05:00.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
MedCity News
DECEMBER 20, 2022
Nearly 90% of Americans prefer to receive their health coverage through an employer versus other means, according to a new survey. Quality, affordability and convenience are the key reasons for why Americans favor employer-sponsored insurance.
Fierce Pharma
DECEMBER 20, 2022
Xeris gets green light to take subcutaneous challenger to AbbVie drug into phase 2. ntaylor. Tue, 12/20/2022 - 06:35.
MedCity News
DECEMBER 20, 2022
Translating complex medical knowledge, and making it available to patients in a simple and easy-to-use way, can make healthcare accessible to those that otherwise may have difficulty.
pharmaphorum
DECEMBER 20, 2022
In the past two decades, global spending on health has doubled. Yet, optimal healthcare remains out of reach for most of the world as many countries continue to struggle with the burden of disease, growing complexity of healthcare, and persistence of health disparities. The problem is not a lack of innovation. Advancements in technology and medicine have made it possible to improve nearly every aspect of care by analysing vast amounts of data, uncovering insights into each person’s disease and e
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
LEVO Health
DECEMBER 20, 2022
Healthcare is a rapidly changing industry, and if you want to stay ahead of the curve, you’ll need to adopt some cutting-edge marketing strategies. As 2023 approaches, there are several strategies you can adopt to improve your healthcare marketing efforts and grow your practice. Adopting the following six marketing strategies may help you stay competitive, bring in new patients, and grow your practice substantially. 6 Medical Marketing Strategies to Adopt in 2023.
Clear Pivot
DECEMBER 20, 2022
When I first started ClearPivot, I developed websites in WordPress. However, I now believe that WordPress is a severe liability that most companies should avoid.
pharmaphorum
DECEMBER 20, 2022
Switzerland’s Idorsia has submitted a new drug application to the FDA for aprocitentan as a treatment for people whose blood pressure remains stubbornly high despite treatment and who are at increased risk of complications like kidney disease and stroke. The dual endothelin receptor antagonist (ERA) has been tipped as a potential $2.5 billion blockbuster by analysts at Jefferies, as there is considerable need for new therapies for people with so-called resistant hypertension.
Legacy MEDSearch
DECEMBER 20, 2022
Empirical Spine, Inc., a medical device company creating a new class of spinal implant, recently completed the final step in the U.S. Food & Drug Administration (FDA) submission process for the LimiFlex Dynamic Sagittal Tether (DST). The Premarket Approval (PMA) submission included Module III, with data and analysis of the two-year results from the pivotal Investigational Device Exemption (IDE) clinical trial comparing LimiFlex DST stabilization versus fusion surgery for degenerative spo
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
pharmaphorum
DECEMBER 20, 2022
The ICR and The Royal Marsden have embarked on an ambitious research collaboration to disrupt the cancer cell ecosystem. Ben Hargreaves explores the project to determine exactly how the partners aim to make the human body an ‘inhospitable environment’ to tumours. Cancer is the major therapeutic focus area for the pharmaceutical industry. Oncology trial starts reached historic highs in 2021, and a record 30 oncology novel active substances were launched globally the same year, according to resear
European Pharmaceutical Review
DECEMBER 20, 2022
FINTEPLA ® ▼ (fenfluramine) oral solution has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) for treating seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients over two years old in the European Union (EU). Commenting on fenfluramine, an oral solution developed by biopharma UCB, this “positive CHMP opinion is a significant regulatory milestone towards providing a new tr
Pharmaceutical Technology
DECEMBER 20, 2022
Biotechnology firm LianBio has announced that Pfizer opted in to secure the right to develop and commercialise the respiratory syncytial virus (RSV) therapeutic candidate, sisunatovir, in Mainland China, Hong Kong, Macau, and Singapore. The deal is pursuant to the existing strategic collaboration of the companies for expanding patient access to new therapeutics in Greater China.
PharmaTimes
DECEMBER 20, 2022
ColoAlert research could identify advanced adenomas among colorectal cancer patients
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
DECEMBER 20, 2022
Japan has granted approval for Bristol-Myers Squibb ’s (BMS) Breyanzi (lisocabtagene maraleucel; liso-cel) as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients. The treatment is indicated for usage in such patients irrespective of autologous hematopoietic stem-cell transplantation status. This approval is based on clinical trial findings in subjects with r/r aggressive B-cell non-Hodgkin lymphoma following first-line therapy.
pharmaphorum
DECEMBER 20, 2022
Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. The Anglo-US company reported the results of the ENHANCE-1 study earlier today, with the first-in-class phosphodiesterase 3 and 4 inhibitor achieving significant improvements in lung function as well as a 36% reduction in the moderate or severe COPD exacerbation rate over 24 weeks.
Pharmaceutical Technology
DECEMBER 20, 2022
Catalyst Pharmaceuticals has signed a definitive agreement with Eisai to acquire the US commercial rights for the latter’s anti-epileptic drug (AED), Fycompa (perampanel) CIII. Under the deal terms, Catalyst will also have an exclusive period to assess, review, and negotiate to buy a rare epilepsy asset in Eisai’s pipeline. Eisai will retain its rights to Fycompa in countries outside the US.
PharmaTimes
DECEMBER 20, 2022
Therapy shows quality of life boost and significant improvement in lung function
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
264 
Let's personalize your content